Related Experiment Video
Updated: Aug 15, 2026
An Orthotopic Bladder Cancer Model for Gene Delivery Studies
Published on: December 1, 2013
Antiangiogenic drugs for chemotherapy of bladder tumours
Romina Rocchetti1, Simona Talevi, Chiara Margiotta
1Institute of Microbiology and Biomedical Sciences, Polytechnic University of Marche, Ancona, Italy.
Background:
Bladder cancers have different angiogenic pathways distinguishing not only papillary from solid tumours, but even papillary superficial from papillary invasive ones, thus representing selective targets for antiangiogenic drugs.
Methods:
The bacterial wall component tecogalan, inhibiting basic fibroblast growth factor (bFGF), the fumagillin derivative TNP-470, inhibiting vascular endothelial growth factor (VEGF), the distamycin A derivative PNU153429, and the tetracycline minocycline were administered to nude mice injected with the human bladder cancer cell lines 639V, causing bFGF-expressing papillary superficial tumours, or T24, causing VEGF-expressing papillary invasive tumours.
Results:
Tecogalan had no effect even on 639V tumour growth, where bFGF was unaffected. TNP-470 only had an effect on T24 tumours, delaying tumour appearance and growth and lowering VEGF; these effects were augmented by adding minocycline. PNU153429 had no effect on 639V tumours, and a slight effect on T24 tumours.
Conclusion:
TNP-470 may represent a selective drug for the treatment of VEGF-expressing invasive papillary bladder tumours.
Insights
Investigating anti-angiogenic drugs for bladder cancer revealed TNP-470 effectively targets VEGF-expressing invasive papillary tumors. This finding offers a selective therapeutic approach for this specific bladder cancer subtype.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Bladder cancers exhibit distinct angiogenic pathways.
- These pathways differ between papillary and solid tumors, and even superficial versus invasive papillary types.
- This heterogeneity suggests specific anti-angiogenic drug targets exist.
Purpose of the Study:
- To evaluate the efficacy of various anti-angiogenic agents against different bladder cancer models.
- To determine if specific drugs target distinct angiogenic pathways in bladder tumors.
Main Methods:
- Nude mice bearing human bladder cancer cell lines (639V for bFGF-expressing, T24 for VEGF-expressing) were treated with tecogalan, TNP-470, PNU153429, and minocycline.
- Tumor growth, appearance, and specific growth factor expression (bFGF, VEGF) were monitored.
Main Results:
- Tecogalan and PNU153429 showed no significant effect on either tumor type.
- TNP-470 demonstrated efficacy against T24 tumors, delaying growth and reducing VEGF levels.
- Minocycline enhanced the effects of TNP-470 on T24 tumors.
Conclusions:
- TNP-470 shows selective activity against VEGF-expressing invasive papillary bladder tumors.
- This suggests TNP-470 could be a targeted therapy for this specific bladder cancer subtype.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:15Drugs that Stabilize Microtubules
01:10Drugs that Destabilize Microtubules
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:10Mechanism of Angiogenesis